If a patient discontinues buprenorphine and uses kratom, will restarting buprenorphine precipitate opioid withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Kratom Can Precipitate Withdrawal When Restarting Buprenorphine

If a patient stops buprenorphine, uses kratom, and then restarts buprenorphine, precipitated withdrawal is possible because kratom acts as a full opioid agonist at mu-receptors, and buprenorphine's high receptor affinity will displace it—just like any other opioid.

Understanding the Mechanism

Kratom contains mitragynine and 7-hydroxymitragynine, which function as mu-opioid receptor agonists 1, 2. When buprenorphine (a partial agonist with extremely high receptor affinity) is administered while these kratom alkaloids occupy opioid receptors, it displaces them and precipitates withdrawal. The FDA label explicitly warns that "buprenorphine may precipitate opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists if administered before the agonist effects of other opioids have subsided" 3.

The clinical evidence confirms this mechanism works identically with kratom. Multiple case reports demonstrate that patients dependent on kratom experience typical opioid withdrawal when kratom is stopped 1, 2, 4, and conversely, naltrexone (an opioid antagonist) precipitates withdrawal in kratom users 5—proving kratom creates true opioid dependence.

Clinical Approach to Buprenorphine Reinduction

The patient must be in mild-to-moderate opioid withdrawal before restarting buprenorphine. This is the same principle used when restarting buprenorphine after any full opioid agonist use 6.

Step-by-Step Protocol:

  1. Wait for withdrawal to emerge: The patient should discontinue kratom and wait until objective withdrawal signs appear (typically 12-24 hours, though kratom's half-life may vary)

  2. Assess withdrawal severity: Use the Clinical Opiate Withdrawal Scale (COWS) to document mild-to-moderate withdrawal (COWS ≥8-12) before administering buprenorphine 7

  3. Initial buprenorphine dosing: Start with 2-4 mg sublingual, repeated at 2-hour intervals if tolerated, until withdrawal symptoms resolve 7, 8

  4. Target first-day dose: Most patients require 4-8 mg total on day one 8

  5. Titrate on day two: Reassess and adjust dose as needed; the total dose given on day 2 becomes the maintenance dose 8

Critical Pitfalls to Avoid

Do not assume kratom is "just a supplement" without opioid activity. The evidence clearly demonstrates kratom creates opioid dependence with tolerance and withdrawal 1, 2, 4, 9, 10. Patients using 7-hydroxymitragynine products (marketed as "7-OH" or "7-Hydroxy") face even higher risk, as this compound has significantly greater mu-receptor potency than standard kratom 9.

If precipitated withdrawal occurs despite following guidelines (increasingly reported with fentanyl and high-potency opioids 11, 12), the management is counterintuitive but evidence-based: give more buprenorphine rapidly. One case report successfully managed precipitated withdrawal by escalating to 20 mg buprenorphine total within hours 12. The standard recommendation is 2 mg buprenorphine every 1-2 hours until symptoms resolve 11, 12.

Special Considerations

The 2020 emergency medicine guidelines emphasize that buprenorphine should only be administered to patients in active opioid withdrawal as confirmed by history and physical examination 7. This applies equally to kratom users. Particular caution is warranted because:

  • Kratom's pharmacokinetics are not well-characterized, making withdrawal timing less predictable
  • Many kratom products contain variable alkaloid concentrations
  • Patients may not recognize or disclose kratom as an "opioid"

Screen specifically for kratom use when taking substance use histories, as patients often view it as a benign herbal supplement rather than an opioid 1, 2, 5. The case of precipitated withdrawal from naltrexone in an undisclosed kratom user highlights this risk 5.

Long-Term Management

Multiple case series demonstrate that buprenorphine effectively treats kratom dependence, withdrawal, and the chronic pain that often drives kratom use 1, 2, 4. Patients successfully transitioned from kratom to buprenorphine maintenance show improvement in pain control, depression, and anxiety symptoms 2. This supports using the same medication-assisted treatment approach for kratom dependence as for traditional opioid use disorder.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.